MiNK Therapeutics Inc (INKT)
1.01
-0.03
(-2.88%)
USD |
NASDAQ |
May 17, 16:00
1.01
0.00 (0.00%)
After-Hours: 20:00
MiNK Therapeutics Cash from Financing (TTM): 4.934M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.934M |
| December 31, 2023 | -0.4072M |
| September 30, 2023 | -0.4071M |
| June 30, 2023 | -0.4095M |
| March 31, 2023 | -0.4907M |
| Date | Value |
|---|---|
| December 31, 2022 | -0.1556M |
| September 30, 2022 | 39.64M |
| June 30, 2022 | 42.42M |
| March 31, 2022 | 46.93M |
| December 31, 2021 | 49.26M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.4907M
Minimum
Mar 2023
49.26M
Maximum
Dec 2021
18.13M
Average
2.389M
Median
Cash from Financing (TTM) Benchmarks
| CareCloud Inc | -12.87M |
| Longeveron Inc | 5.262M |
| RenovoRx Inc | 10.42M |
| MSP Recovery Inc | 29.02M |
| Adlai Nortye Ltd | 9.238M |